BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 34364110)

  • 1. Real world utilization of REGEN-COV2 at a community hospital.
    Ash J; Leavitt R; Dietrich T; Schritter S; Wells J; Santarelli A; Ashurst J
    Am J Emerg Med; 2021 Dec; 50():129-131. PubMed ID: 34364110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.
    Verderese JP; Stepanova M; Lam B; Racila A; Kolacevski A; Allen D; Hodson E; Aslani-Amoli B; Homeyer M; Stanmyre S; Stevens H; Garofalo S; Henry L; Venkatesan C; Gerber LH; Motew SJ; Jones JS; Younossi ZM
    Clin Infect Dis; 2022 Mar; 74(6):1063-1069. PubMed ID: 34166513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
    Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Musser BJ; Soo Y; Rofail D; Im J; Perry C; Pan C; Hosain R; Mahmood A; Davis JD; Turner KC; Hooper AT; Hamilton JD; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Kohli A; Sachdeva Y; Graber X; Kowal B; DiCioccio T; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
    N Engl J Med; 2021 Jan; 384(3):238-251. PubMed ID: 33332778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
    Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
    J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real World Utilization of Bamlanivimab at a Rural Community Hospital.
    Leavitt R; Ash J; Hasenbalg P; Santarelli A; Dietrich T; Schritter S; Wells J; Dawson A; Ashurst J
    Cureus; 2021 Nov; 13(11):e19747. PubMed ID: 34938624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).
    Mayer C; VanHise K; Caskey R; Naqvi M; Burwick RM
    Obstet Gynecol; 2021 Dec; 138(6):937-939. PubMed ID: 34583385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.
    Nomura T; Kitagawa H; Kakimoto M; Kaiki Y; Nazmul T; Miyamori D; Omori K; Shigemoto N; Ito M; Sakaguchi T; Ohge H
    J Infect Chemother; 2022 Jul; 28(7):912-917. PubMed ID: 35370078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.
    Sakurai A; Marshall S; Ogasawara T; Ogasawara T; Aoka Y; Sakura H; Uchigata Y; Ogawa T
    J Infect Chemother; 2022 Jul; 28(7):943-947. PubMed ID: 35414436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic.
    Levey NH; Forrest AD; Spielman DW; Easley KA; Dude CM; Badell ML
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100673. PubMed ID: 35671984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
    Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
    JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
    McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
    JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
    Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Xiao J; Hooper AT; Hamilton JD; Musser BJ; Rofail D; Hussein M; Im J; Atmodjo DY; Perry C; Pan C; Mahmood A; Hosain R; Davis JD; Turner KC; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Roque-Guerrero L; Acloque G; Aazami H; Cannon K; Simón-Campos JA; Bocchini JA; Kowal B; DiCioccio AT; Soo Y; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
    N Engl J Med; 2021 Dec; 385(23):e81. PubMed ID: 34587383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
    O'Brien MP; Forleo-Neto E; Musser BJ; Isa F; Chan KC; Sarkar N; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Hou P; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
    N Engl J Med; 2021 Sep; 385(13):1184-1195. PubMed ID: 34347950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.
    Wolf J; Abzug MJ; Wattier RL; Sue PK; Vora SB; Zachariah P; Dulek DE; Waghmare A; Olivero R; Downes KJ; James SH; Pinninti SG; Yarbrough A; Aldrich ML; MacBrayne CE; Soma VL; Grapentine SP; Oliveira CR; Hayes M; Kimberlin DW; Jones SB; Bio LL; Morton TH; Hankins JS; Maron GM; Timberlake K; Young JL; Orscheln RC; Schwenk HT; Goldman DL; Groves HE; Huskins WC; Rajapakse NS; Lamb GS; Tribble AC; Lloyd EC; Hersh AL; Thorell EA; Ratner AJ; Chiotos K; Nakamura MM
    J Pediatric Infect Dis Soc; 2021 May; 10(5):629-634. PubMed ID: 33388760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan.
    Terakawa K; Katagiri D; Shimada K; Sato L; Takano H
    CEN Case Rep; 2022 Aug; 11(3):328-332. PubMed ID: 35000134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2.
    Arikawa S; Fukuoka K; Nakamoto K; Kunitomo R; Matsuno Y; Shimazaki T; Saraya T; Kawakami T; Kishimoto M; Komagata Y; Kurai D; Ishi H; Kaname S
    Clin Exp Nephrol; 2022 May; 26(5):476-485. PubMed ID: 35182277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Davey VJ; Goodman A; Higgs ES; Murray DD; Murray TA; Paredes R; Parmar MKB; Phillips AN; Reilly C; Sharma S; Dewar RL; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    N Engl J Med; 2021 Mar; 384(10):905-914. PubMed ID: 33356051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV.
    Sasaki H; Miyata N; Yoshimura Y; Tachikawa N
    Infection; 2022 Jun; 50(3):771-774. PubMed ID: 35181864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.